The Pharmacy Times® Breast Cancer Resource Center is a comprehensive resource for clinical news and expert insights on issues related to cancers that occur in the breast, including invasive ductal carcinoma, invasive lobular carcinoma, and less common forms of the disease.
May 2nd 2024
The screenings should be conducted every other year, beginning at age 40 and continuing through age 74, according to the new recommendation.
Daily Medication Pearl: Sacituzumab govitecan-hziy (Trodelvy) for Breast Cancer
November 16th 2021Sacituzumab govitecan-hziy is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received 2 or more prior systemic therapies, at least 1 of which for metastatic disease.
Read More
Study: 3% of Cancers In the US Preventable Through Weekly Physical Activity
November 2nd 2021Study finds that 16.9% of stomach cancers, 11.9% of endometrial cancers, 11.0% of kidney cancers, 9.3% of colon cancers, 8.1% of esophageal cancers, 6.5% of female breast cancers, and 3.9% of urinary bladder cancers were associated with a low level of exercise.
Read More
Elacestrant Improves Outcomes for Certain Patients With Breast Cancer
October 29th 2021The study was designed to evaluate elacestrant as a monotherapy compared to the standard of care for the treatment of estrogen receptor-positive/human epidermal growth factor receptor 2 advanced or metastatic breast cancer.
Read More
Oncology Overview: Sacituzumab Govitecan-hziy (Trodelvy) for Triple-Negative Breast Cancer
October 27th 2021Sacituzumab govitecan-hziy (Trodelvy) is indicated for the treatment of patients with triple-negative breast cancer who have received 2 prior therapies at minimum for metastatic disease.
Read More
Study: Artificial Intelligence Can Predict Risk of Recurrence for Women With Common Breast Cancer
October 15th 2021They added that this is one of the first proofs of concept illustrating the power of an AI model for identifying parameters associated with relapse that the human brain could not detect.
Read More
Oncology Overview: Tucatinib for Advanced Unresectable or Metastatic HER2-Positive Breast Cancer
September 16th 2021Tucatinib is indicated to treat adults with advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have already received at least 1 anti-HER2-based regimen in the metastatic setting.
Read More
Study Identifies How PARP Inhibitors Fight BRCA1, BRCA2 Tumor Cells
September 8th 2021This drug class works by interfering with the ability of cancer cells to repair themselves after experiencing damage to their DNA, but how PARP inhibitors selectively kill cancer cells was previously unknown.
Read More
Study: Physical Activity Associated With Better Cognition in Breast Cancer Patients
August 24th 2021This research lays the foundation for future clinical trials aimed at investigating whether moderate to vigorous exercise can minimize “chemo brain,” which is a decline in cognitive function many patients with breast cancer experience.
Read More